FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Dr. Reddys Form-483 Released

FDA releases a Form-483 from a February inspection at Dr. Reddys oncology drug formulation manufacturing facility in Duvvada, Visakhapatnam, India.

Human Drugs

FDA Approves Genentech Drug for Multiple Sclerosis

FDA approves a Genentech NDA for Ocrevus (ocrelizumab) for treating adult patients with relapsing forms of multiple sclerosis and primary progressive ...

Arizona Approves First State Off-Label Info Bill

Arizona approves the first state legislation to authorize truthful communication on off-label uses between drug and medical device companies and healt...

FDA General

Gottlieb Sets Recusals from Many Drug Companies

FDA commissioner nominee Scott Gottlieb says he will recuse himself for one year from decisions involving about 20 healthcare companies he has a finan...

Human Drugs

FDA Complete Response on Mylan Generic Advair

FDA issues Mylan a complete response letter on its ANDA for a generic copy of GlaxoSmithKlines asthma therapy Advair Diskus (fluticasone propionate 10...

Medical Devices

FDA Clears NuVasive Interbody System

FDA clears a NuVasive 510(k) for the CoRoent Small Interbody System indicated for intervertebral body fusion at multiple contiguous levels in the cerv...

Human Drugs

BMS, Research Groups Join in Immuno-Oncology Studies

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute announce a multi-year clinical research collabor...

Medical Devices

Bodycad Knee System Cleared by FDA

FDA clears a Bodycad 510(k) for its Bodycad Unicompartmental Knee System, a joint reconstruction implant system.

Human Drugs

Advisory Panel Unanimously Backs New Rituxan Formulation

FDAs Oncologic Drugs Advisory Committee votes unanimously (11 to 0) that the benefit-risk of rituximab/hyaluronidase for subcutaneous injection was fa...

Human Drugs

McCaskill Seeking Drug Company Opioid Info

Sen. McCaskill asks five drug companies for information on their knowledge of risk for opioid abuse and their marketing practices for the drugs.